Intestinal Absorption of Miltefosine: Contribution of Passive Paracellular Transport
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This study aimed to characterize the transepithelial transport of miltefosine (HePC), the first orally effective drug against visceral leishmaniasis, across the intestinal barrier to further understand its oral absorption mechanism.
Materials and Methods
Caco-2 cell monolayers were used as an in vitro model of the human intestinal barrier. The roles of active and passive mechanisms in HePC intestinal transport were investigated and the relative contributions of the transcellular and paracellular routes were estimated.
HePC transport was observed to be pH-independent, partially temperature-dependent, linear as a function of time and non-saturable as a function of concentration. The magnitude of HePC transport was quite similar to that of the paracellular marker mannitol, and EDTA treatment led to an increase in HePC transport. Furthermore, HePC transport was found to be similar in the apical-to-basolateral and basolateral-to-apical directions, strongly suggesting that HePC exhibits non-polarized transport and that no MDR-mediated efflux was involved.
These results demonstrate that HePC crosses the intestinal epithelium by a non-specific passive pathway and provide evidence supporting a concentration-dependent paracellular transport mechanism, although some transcellular diffusion cannot be ruled out. Considering that HePC opens epithelial tight junctions, this study shows that HePC may promote its own permeation across the intestinal barrier.
- S. Sundar, F. Rosenkaimer, M. K. Makharia, A. K. Goyal, A. K. Mandal, A. Voss, P. Hilgard, and H. W. Murray. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 352:1821–1823 (1998). CrossRef
- S. Sundar, and H. W. Murray. Availability of miltefosine for the treatment of kala-azar in India. Bull. World Health Organ. 83:394–395 (2005).
- S. Sundar, T. K. Jha, C. P. Thakur, J. Engel, H. Sindermann, C. Fischer, K. Junge, A. Bryceson, and J. Berman. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347:1739–1746 (2002). CrossRef
- A. Breiser, D. J. Kim, E. Fleer, W. Damenz, A. Drube, M. Berger, G. Nagel, H. Eibl, and C. Unger. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids. 22:925–926 (1987). CrossRef
- N. Marschner, J. Kötting, H. Eibl, and C. Unger. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother. Pharmacol. 31:18–22 (1992). CrossRef
- J. Kotting, N. W. Marschner, W. Neumuller, C. Unger, and H. Eibl. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res. 34:131–142 (1992).
- I. Rey Gomez-Serranillos, J. Minones Jr, P. Dynarowicz-Latka, E. Iribarnegaray, and M. Casas. Study of the p-A isotherms of miltefosine monolayers spread at the air/water interface. Phys. Chem. Chem. Phys. 6:1580–1586 (2004). CrossRef
- C. Matos, H. Chaimovich, J. L. Lima, I. M. Cuccovia, and S. Reis. Effect of liposomes on the rate of alkaline hydrolysis of indomethacin and acemetacin. J. Pharm. Sci. 90:298–309 (2001). CrossRef
- P. S. De Araujo, M. Y. Rosseneu, J. M. Kremer, E. J. van Zoelen, and G. H. de Haas. Structure and thermodynamic properties of the complexes between phospholipase A2 and lipid micelles. Biochemistry. 18:580–586 (1979). CrossRef
- J. Kotting, N. W. Marschner, C. Unger, and H. Eibl. Determination of alkylphosphocholines and of alkyl-glycero-phosphocholines in biological fluids and tissues. Prog. Exp. Tumor Res. 34:6–11 (1992).
- D. R. Hoffman, L. H. Hoffman, and F. Snyder. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. Cancer Res. 46:5803–5809 (1986).
- W. J. Van Blitterswijk, H. Hilkmann, and G. A. Storme. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids. 22:820–823 (1987). CrossRef
- F. J. Perez-Victoria, F. Gamarro, M. Ouellette, and S. Castanys. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278:49965–49971 (2003). CrossRef
- P. Artursson. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476–482 (1990). CrossRef
- I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 96:736–749 (1989).
- C. C. Geilen, A. Samson, T. Wieder, H. Wild, and W. Reutter. Synthesis of hexadecylphospho[methyl-14C]-choline. J. Labelled Compd. Radiopharm. 31:1071–1076 (1992). CrossRef
- H. Eibl, and P. Woolley. A general synthetic method for enantiomerically pure ester and ether lysophospholipids. Chem. Phys. Lipids. 47:63–68 (1988). CrossRef
- T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:55–63 (1983). CrossRef
- T. Decker, and M. L. Lohmann-Matthes. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods. 115:61–69 (1988). CrossRef
- C. Ménez, M. Buyse, H. Chacun, R. Farinotti, and G. Barratt. Modulation of intestinal barrier properties by miltefosine. Biochem. Pharmacol. 71:486–496 (2006). CrossRef
- B. L. Clarke, and P. H. Weigel. Recycling of the asialoglycoprotein receptor in isolated rat hepatocytes. ATP depletion blocks receptor recycling but not a single round of endocytosis. J. Biol. Chem. 260:128–133 (1985).
- P. Artursson, and C. Magnusson. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 79:595–600 (1990). CrossRef
- L. S. Gan, P. H. Hsyu, J. F. Pritchard, and D. Thakker. Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm. Res. 10:1722–1725 (1993). CrossRef
- V. Pade, and S. Stavchansky. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 14: 1210–1215 (1997). CrossRef
- A. Tsuji, H. Takanaga, I. Tamai, and T. Terasaki. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm. Res. 11: 30–37 (1994). CrossRef
- M. E. Cavet, M. West, and N. L. Simmons. Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells. Antimicrob. Agents Chemother. 41:2693–2698 (1997).
- P. Artursson, A. L. Ungell, and J. E. Lofroth. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm. Res. 10:1123–1129 (1993). CrossRef
- L. S. Gan, T. Niederer, C. Eads, and D. Thakker. Evidence for predominantly paracellular transport of thyrotropin-releasing hormone across Caco-2 cell monolayers. Biochem. Biophys. Res. Commun. 197:771–777 (1993). CrossRef
- I. J. Hidalgo, and R. T. Borchardt. Transport of bile acids in a human intestinal epithelial cell line, Caco-2. Biochim. Biophys. Acta. 1035:97–103 (1990).
- M. Rybczynska, R. Liu, P. Lu, F. J. Sharom, E. Steinfels, A. D. Pietro, M. Spitaler, H. Grunicke, and J. Hofmann. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer. 84:1405–1411 (2001). CrossRef
- H. M. Said, A. Ortiz, and T. Y. Ma. A carriermediated mechanism for pyridoxine uptake by human intestinal epithelial Caco2 cells: regulation by a PKAmediated pathway. Am. J. Physiol. Cell Physiol. 285:C1219–1225 (2003).
- A. Leroy, G. K. de Bruyne, L. C. Oomen, and M. M. Mareel. Alkylphospholipids reversibly open epithelial tight junctions. Anticancer Res. 23:27–32 (2003).
- P. D. Ward, H. Ouyang, and D. R. Thakker. Role of phospholipase C-beta in the modulation of epithelial tight junction permeability. J. Pharmacol. Exp. Ther. 304:689–698 (2003). CrossRef
- D. Z. Liu, E. L. LeCluyse, and D. R. Thakker. Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J. Pharm. Sci. 88:1161–1168 (1999). CrossRef
- A. Amelsberg, C. D. Schteingart, J. Stein, W. J. Simmonds, G. A. Sawada, N. F. Ho, and A. F. Hofmann. Intestinal absorption of sodium dodecyl sulfate in the rodent: evidence for paracellular absorption. Am. J. Physiol. 272:G498–506 (1997).
- D. E. Leahy, J. Lynch, R. E. Finney, and D. C. Taylor. Estimation of sieving coefficients of convective absorption of drugs in perfused rat jejunum. J. Pharmacokinet. Biopharm. 22:411–429 (1994). CrossRef
- H. N. Nellans. Mechanisms of peptide and protein absorption : (1) Paracellular intestinal transport: modulation of absorption. Adv. Drug Deliv. Rev. 7:339–364 (1991). CrossRef
- J. R. Pappenheimer, M. L. Karnovsky, and J. E. Maggio. Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. J. Pharmacol. Exp. Ther. 280:292–300 (1997).
- V. Pade, and S. Stavchansky. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J. Pharm. Sci. 87:1604–1607 (1998). CrossRef
- P. Artursson, K. Palm, and K. Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46:27–43 (2001). CrossRef
- E. Biganzoli, L. A. Cavenaghi, R. Rossi, M. C. Brunati, and M. L. Nolli. Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. Il Farmaco. 54:594–599 (1999). CrossRef
- K. M. Hillgren, A. Kato, and R. T. Borchardt. In vitro systems for studying intestinal drug absorption. Med. Res. Rev. 15:83–109 (1995). CrossRef
- J. Berman. Miltefosine to treat leishmaniasis. Expert Opin. Pharmacother. 6:1381–1388 (2005). CrossRef
- B. Arnold, R. Reuther, and H. U. Weltzien. Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim. Biophys. Acta. 530:47–55 (1978).
- P. K. Hanson, L. Malone, J. Birchmore, and J. Nichols. Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J. Biol. Chem. 278:36041–36050 (2003). CrossRef
- F. J. Perez-Victoria, S. Castanys, and F. Gamarro. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 47:2397–2403 (2003). CrossRef
- E. E. Kelley, E. J. Modest, and C. P. Burns. Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem. Pharmacol. 45:2435–2439 (1993). CrossRef
- F. Uberall, H. Oberhuber, K. Maly, J. Zaknun, L. Demuth, and H. H. Grunicke. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 51:807–812 (1991).
- E. C. Heesbeen, G. Rijksen, H. G. van Heugten, and L. F. Verdonck. Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3. Leuk. Res. 19:417–425 (1995). CrossRef
- Intestinal Absorption of Miltefosine: Contribution of Passive Paracellular Transport
Volume 24, Issue 3 , pp 546-554
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- intestinal absorption
- paracellular transport
- Industry Sectors
- Author Affiliations
- 1. Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, IFR 141, University Paris-Sud 11, Faculté de Pharmacie, 5 rue J.B. Clément, Châtenay-Malabry Cedex, F-92296, France
- 2. Laboratoire de Pharmacie Clinique UPRES 2706, IFR 141, University Paris-Sud 11, Faculté de Pharmacie, 5 rue J.B. Clément, Châtenay-Malabry Cedex, F-92296, France
- 3. Département d’Ingénierie et d’Etudes des Protéines (DIEP), CEA, Bâtiment 152, CEA/Saclay, Gif-sur-Yvette, F-91191, France